Japan Approves Zoladex LA (Goserelin) for Prostate Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Japan Approves Zoladex LA (Goserelin) for Prostate Cancer

LONDON, ENGLAND -- January 17, 2002 -- AstraZeneca announced today that Zoladex® LA (goserelin acetate 10.8mg) for prostate cancer treatment has received marketing approval in Japan.
This follows a positive report made by Japan’s Ministry of Health, Labour and Welfare’s (MHLW) Pharmaceutical Affairs Council in December 2001. Zoladex LA (Longer Acting) is the first Luteinizing Hormone-Releasing Hormone analogue (LHRHa) available in Japan with an injection that is effective for three months, and adds to the 3.6mg depot (monthly) formulation, already widely used. The approved indication in Japan is for the treatment of prostate cancer.

Zoladex LA is already approved in 78 countries and has replaced the monthly depot in the majority of patients on this therapy in all major markets, due to the benefits offered. Benefits of the longer-acting formulation include a more convenient therapy for prostate cancer patients and improved compliance.

Zoladex is a widely prescribed LHRHa therapy administered by a subcutaneous depot injection. These agents work by reducing testosterone production. Zoladex is one of the world’s leading therapies for prostate cancer, with proven survival data, offering similar overall survival benefits and improvements in quality of life compared to surgical castration (orchidectomy).

In addition, in the adjuvant setting, Zoladex is the only LHRHa demonstrating proven disease-free survival as well as overall survival benefits, compared with primary treatment alone.

First launched in 1987, Zoladex is available in more than 100 countries. Zoladex is the world’s number three anti-cancer drug with indications in prostate and breast cancer and the top oncology product for AstraZeneca, with annual sales in excess of $700 million. Japan is AstraZeneca’s second biggest market.

SOURCE: AstraZeneca

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities